Among patients with limited-stage small cell lung cancer, the benefits of consolidation Imfinzi were seen across a number of ...

This surge came after the company announced approval to import and distribute Durvalumab (Imfinzi) infusion in two dosages.

AstraZeneca’s Imfinzi recently became the first PD-1/L1 inhibitor to deliver a patient survival win in muscle-invasive ...

The company has received approval to import, sell, and distribute Durvalumab Solution for infusion (Imfinzi) from the Central ...

This is to inform you that AstraZeneca Pharma India Limited has received permission from the Central Drugs Standard Control ...

The stock is trading above its 5-day, 10-day, 20-day, 30-day, 50-day, 100-day, 150-day, and 200-day simple moving averages ...

The uptick in AstraZeneca share price came after the company announced that it has received permission to import for sale and ...

Astrazeneca Pharma India said that it has received permission from Central Drugs Standard Control Organisation (CDSCO) to import for sale and distribution of Durvalumab solutions (IMFINZI) in India.

Patients with limited-stage small cell lung cancer saw improvements in progression-free survival and overall survival with ...

The company has received permission to import for sale and distribution of Durvalumab 120 mg/2.4 mL and 500 mg/10 mL solution ...

The NIAGARA trial with Imfinzi is the first study to show an OS benefit in both the neoadjuvant and adjuvant settings.